Bausch Health Companies Inc. faced a notable decline in stock value, dropping 3.20% in the last trading session.
Bausch Health Companies Inc. (BHC.TO) experienced a significant downturn in its stock price, closing at CA$6.66 after a 3.20% drop. This decline raises concerns among Canadian investors about the company's short-term performance and market positioning.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.61B
52W high
$11.97
52W low
$6.45
1W change
-1.15%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 1.9% over the next 12 months.
Consensus
No RatingAvg. Target
C$7.01
+1.9% Upside
Current Price
C$6.88
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
49.7%
Annualized
90-Day Vol
42.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.48 | C$5.46 – C$7.70 |
| 60 trading days | C$6.11 | C$4.79 – C$7.78 |
| 90 trading days | C$5.75 | C$4.28 – C$7.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Bausch Health's recent performance suggests potential underlying issues that may affect future growth and stability.
Bausch Health's stock drops 3.20% in one day.
With a market cap of CA$2.61 billion and a closing price of CA$6.66, Bausch Health's financial metrics raise red flags for investors.
Bull case
Despite the recent decline, Bausch Health is working to expand its product offerings. The recent approval of PrOKEDI® in Quebec could open up long-term growth opportunities for the company.
Bear case
The stock's decline reflects broader concerns about the company's financial health. With a negative profit margin and no P/E ratio, investors may face challenges ahead.
Recent Performance Overview
In the latest trading session, Bausch Health Companies Inc. saw a decline of 3.20%, closing at CA$6.66. This drop is part of a concerning trend for the company, which has struggled with profitability, evidenced by a negative profit margin of -11.47%. Investors are left questioning the company's ability to recover and sustain growth in a competitive market.
Market Reactions and Future Outlook
The market's reaction to Bausch Health's recent performance suggests a lack of confidence among investors. The upcoming announcement of the second quarter 2026 results on July 29, 2026, could provide critical insights into the company's financial health and strategic direction. However, with a market cap of CA$2.61 billion, the pressure is on for Bausch Health to demonstrate a turnaround.
Advertisement
